drugset / Trial / NCT04293172
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to compare the effect of ticagrelor vs placebo for the reduction of Vaso-Occlusive crises in paediatric patients with Sickle Cell Disease
Timeline
- Start
- 2020-06-30
- Primary completion
- 2022-10-10
- Completion
- 2022-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ticagrelor | Small molecule | 5 mg | — |
| Subject | Ticagrelor | Small molecule | 10 mg | — |
| Subject | Ticagrelor | Small molecule | 15 mg | — |
| Subject | Ticagrelor | Small molecule | 30 mg | — |
| Subject | Ticagrelor | Small molecule | 45 mg | — |